Search Results - "GO, R."

Regulation and role of the transcription factor IRF5 in innate immune responses and systemic lupus erythematosus by Ban, Tatsuma, Sato, Go R, Tamura, Tomohiko

“…Abstract The transcription factor interferon regulatory factor-5 (IRF5) plays an important role in innate immune responses via the TLR-MyD88 (Toll-like…”
Get full text

Genetic and chemical inhibition of IRF5 suppresses pre-existing mouse lupus-like disease by Ban, Tatsuma, Kikuchi, Masako, Sato, Go R., Manabe, Akio, Tagata, Noriko, Harita, Kayo, Nishiyama, Akira, Nishimura, Kenichi, Yoshimi, Ryusuke, Kirino, Yohei, Yanai, Hideyuki, Matsumoto, Yoshiko, Suzuki, Shuichi, Hihara, Hiroe, Ito, Masashi, Tsukahara, Kappei, Yoshimatsu, Kentaro, Yamamoto, Tadashi, Taniguchi, Tadatsugu, Nakajima, Hideaki, Ito, Shuichi, Tamura, Tomohiko

“…The transcription factor IRF5 has been implicated as a therapeutic target for the autoimmune disease systemic lupus erythematosus (SLE). However, IRF5…”
Get full text

Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents by Majithia, N, Rajkumar, S V, Lacy, M Q, Buadi, F K, Dispenzieri, A, Gertz, M A, Hayman, S R, Dingli, D, Kapoor, P, Hwa, L, Lust, J A, Russell, S J, Go, R S, Kyle, R A, Kumar, S K

“…Outcomes for patients with multiple myeloma (MM) have improved in recent years owing to use of novel agents and high-dose therapy followed by autologous stem…”
Get full text

Lyn Kinase Suppresses the Transcriptional Activity of IRF5 in the TLR-MyD88 Pathway to Restrain the Development of Autoimmunity by Ban, Tatsuma, Sato, Go R., Nishiyama, Akira, Akiyama, Ai, Takasuna, Marie, Umehara, Marina, Suzuki, Shinsuke, Ichino, Motohide, Matsunaga, Satoko, Kimura, Ayuko, Kimura, Yayoi, Yanai, Hideyuki, Miyashita, Sadakazu, Kuromitsu, Junro, Tsukahara, Kappei, Yoshimatsu, Kentaro, Endo, Itaru, Yamamoto, Tadashi, Hirano, Hisashi, Ryo, Akihide, Taniguchi, Tadatsugu, Tamura, Tomohiko

“…Interferon regulatory factor-5 (IRF5), a transcription factor critical for the induction of innate immune responses, contributes to the pathogenesis of the…”
Get full text

Association of higher diastolic blood pressure levels with cognitive impairment by TSIVGOULIS, G, ALEXANDROV, A. V, WADLEY, V. G, UNVERZAGT, F. W, GO, R. C. P, MOY, C. S, KISSELA, B, HOWARD, G

“…We evaluated the cross-sectional relationship of blood pressure (BP) components with cognitive impairment after adjusting for potential confounders. Reasons…”
Get full text

“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience by Vaxman, I., Abeykoon, J., Dispenzieri, A., Kumar, S. K., Buadi, F., Lacy, M. Q., Dingli, D., Hwa, Y., Fonder, A., Hobbs, M., Reeder, C., Sher, T., Hayman, S., Kourelis, T., Warsame, R., Muchtar, E., Leung, N., Go, R., Gonsalves, W., Siddiqui, M., Kyle, R. A., Rajkumar, S. V., Kristen, McCullough, Kapoor, P., Gertz, M. A.

“…Belantamab mafodotin is a highly selective targeted therapy for multiple myeloma. It targets the B cell maturation antigen (BCMA) on plasma cells and showed…”
Get full text

External cavity quantum cascade lasers with ultra rapid acousto-optic tuning by Lyakh, A., Barron-Jimenez, R., Dunayevskiy, I., Go, R., Patel, C. Kumar N.

“…We report operation of tunable external cavity quantum cascade lasers with emission wavelength controlled by an acousto-optic modulator (AOM). A long-wave…”
Get full text

Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category by Muchtar, E, Dispenzieri, A, Kumar, S K, Ketterling, R P, Dingli, D, Lacy, M Q, Buadi, F K, Hayman, S R, Kapoor, P, Leung, N, Chakraborty, R, Gonsalves, W, Warsame, R, Kourelis, T V, Russell, S, Lust, J A, Lin, Y, Go, R S, Zeldenrust, S, Kyle, R A, Rajkumar, S V, Gertz, M A

“…The significance of interphase fluorescence in situ hybridization (iFISH) by regimen type was assessed in 692 immunoglobulin light-chain (AL) amyloidosis…”
Get full text

Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival by Muchtar, E, Dispenzieri, A, Kumar, S K, Buadi, F K, Lacy, M Q, Zeldenrust, S, Hayman, S R, Leung, N, Kourelis, T V, Gonsalves, W, Chakraborty, R, Russell, S, Dingli, D, Lust, J A, Lin, Y, Kapoor, P, Go, R, Kyle, R A, Rajkumar, S V, Gertz, M A

“…Immunoparesis is an adverse prognostic marker in plasma cell proliferative disorders. Its impact in AL amyloidosis has not been explored in depth. Newly…”
Get full text

Erdheim–Chester disease: expanding the spectrum of cutaneous manifestations by Kobic, A., Shah, K.K., Schmitt, A.R., Goyal, G., Go, R.S., Guo, R., Rech, K.L., Sartori‐Valinotti, J.C.

“…Summary Background Erdheim–Chester disease (ECD) is a rare condition and there is limited information available regarding its cutaneous manifestations…”
Get full text

3 W continuous-wave room temperature single-facet emission from quantum cascade lasers based on nonresonant extraction design approach by Lyakh, A., Maulini, R., Tsekoun, A., Go, R., Pflügl, C., Diehl, L., Wang, Q. J., Capasso, Federico, Patel, C. Kumar N.

“…A strain-balanced, InP-based quantum cascade laser structure, designed for light emission at 4.6   μ m using a new nonresonant extraction design approach, was…”
Get full text

A mathematical model of aortic aneurysm formation by Hao, Wenrui, Gong, Shihua, Wu, Shuonan, Xu, Jinchao, Go, Michael R, Friedman, Avner, Zhu, Dai

“…Abdominal aortic aneurysm (AAA) is a localized enlargement of the abdominal aorta, such that the diameter exceeds 3 cm. The natural history of AAA is…”
Get full text

Irf5 siRNA-loaded biodegradable lipid nanoparticles ameliorate concanavalin A-induced liver injury by Kawase, Wataru, Kurotaki, Daisuke, Suzuki, Yuta, Ishihara, Hiroshi, Ban, Tatsuma, Sato, Go R., Ichikawa, Juri, Yanai, Hideyuki, Taniguchi, Tadatsugu, Tsukahara, Kappei, Tamura, Tomohiko

“…RNA interference-based gene silencing drugs are attracting attention for treating various diseases. Lipid nanoparticles (LNPs) are carriers that efficiently…”
Get full text

Natural history of t(11;14) multiple myeloma by Lakshman, A, Alhaj Moustafa, M, Rajkumar, S V, Dispenzieri, A, Gertz, M A, Buadi, F K, Lacy, M Q, Dingli, D, Fonder, A L, Hayman, S R, Hobbs, M A, Gonsalves, W I, Hwa, Y L, Kapoor, P, Leung, N, Go, R S, Lin, Y, Kourelis, T V, Lust, J A, Russell, S J, Zeldenrust, S R, Kyle, R A, Kumar, S K

“…Translocation (11;14) on interphase fluorescent in situ hybridization in plasma cells is regarded as a standard risk prognostic marker in multiple myeloma…”
Get full text

Clinical features and outcomes of extramedullary myeloid sarcoma in the United States: analysis using a national data set by Goyal, G, Bartley, A C, Patnaik, M M, Litzow, M R, Al-Kali, A, Go, R S

Get full text

Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma by Kaufman, G P, Gertz, M A, Dispenzieri, A, Lacy, M Q, Buadi, F K, Dingli, D, Hayman, S R, Kapoor, P, Lust, J A, Russell, S, Go, R S, Hwa, Y L, Kyle, R A, Rajkumar, S V, Kumar, S K

“…Early high-dose therapy (HDT), consisting of high-dose melphalan and autologous stem cell transplantation following doublet or triplet novel agent induction,…”
Get full text

Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma by Binder, M, Rajkumar, S V, Ketterling, R P, Greipp, P T, Dispenzieri, A, Lacy, M Q, Gertz, M A, Buadi, F K, Hayman, S R, Hwa, Y L, Zeldenrust, S R, Lust, J A, Russell, S J, Leung, N, Kapoor, P, Go, R S, Gonsalves, W I, Kyle, R A, Kumar, S K

“…Fluorescence in situ hybridization evaluation is essential for initial risk stratification in multiple myeloma. While the presence of specific cytogenetic…”
Get full text

Correction: Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design by Vaxman, I., Kumar, S. K., Buadi, F., Lacy, M. Q., Dingli, D., Hwa, Y., Fonder, A., Hobbs, M., Hayman, S., Kourelis, T., Warsame, R., Muchtar, E., Leung, N., Kapoor, P., Grogan, M., Go, R., Lin, Y., Gonsalves, W., Siddiqui, M., Kyle, R. A., Rajkumar, S. V., Gertz, M. A., Dispenzieri, A.

Get full text

Vascular risk factors and cognitive impairment in a stroke-free cohort by UNVERZAGT, F. W, MCCLURE, L. A, HOWARD, V, HOWARD, G, WADLEY, V. G, JENNY, N. S, GO, R. C, CUSHMAN, M, KISSELA, B. M, KELLEY, B. J, KENNEDY, R, MOY, C. S

“…To examine vascular risk factors, as measured by the Framingham Stroke Risk Profile (FSRP), to predict incident cognitive impairment in a large, national…”
Get full text

Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design by Vaxman, I., Kumar, S. K., Buadi, F., Lacy, M. Q., Dingli, D., Hwa, Y., Fonder, A., Hobbs, M., Hayman, S., Kourelis, T., Warsame, R., Muchtar, E., Leung, N., Kapoor, P., Grogan, M., Go, R., Lin, Y., Gonsalves, W., Siddiqui, M., Kyle, R. A., Rajkumar, S. V., Gertz, M. A., Dispenzieri, A.

Get full text